AN2 Therapeutics
ANTX
52 hedge funds and large institutions have $74.8M invested in AN2 Therapeutics in 2026 Q1 according to their latest regulatory filings, with 25 funds opening new positions, 13 increasing their positions, 8 reducing their positions, and 10 closing their positions.
657% more capital invested
Capital invested by funds: $9.88M → $74.8M (+$64.9M)
150% more first-time investments, than exits
New positions opened: 25 | Existing positions closed: 10
63% more repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 8
37% more funds holding
Funds holding: 38 → 52 (+14)
29.29% more ownership
Funds ownership: 31.62% → 60.92% (+29%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VC
Vivo Capital
Palo Alto,
California
|
+$6.51M |
| 2 |
CC
Commodore Capital
New York
|
+$4.82M |
| 3 |
Millennium Management
New York
|
+$4.39M |
| 4 |
SSC
Spruce Street Capital
New York
|
+$3.43M |
| 5 |
Adage Capital Partners
Boston,
Massachusetts
|
+$2.06M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PLC
Peapod Lane Capital
Bedford Hills,
New York
|
-$1.1M |
| 2 |
P
Pfizer
New York
|
-$815K |
| 3 |
Bank of Montreal
Toronto,
Ontario, Canada
|
-$334K |
| 4 |
Renaissance Technologies
New York
|
-$289K |
| 5 |
LCM
Landscape Capital Management
Englewood,
New Jersey
|
-$276K |
ANTX Hedge Fund Activity: Q1 2026 in Review
52 of the 8,206 institutional investors tracked by Wall St. Rank reported a position in AN2 Therapeutics (ANTX) for Q1 2026, worth a combined $74.8M — up 657% from $9.88M a quarter earlier.
Buyers outnumbered sellers: 25 funds opened new ANTX positions and 10 closed out — a net gain of 15 holders — while 13 added to existing stakes and 8 trimmed.
The largest buyer was Vivo Capital, opening a new position worth an estimated $6.51M. The largest seller was Peapod Lane Capital, cutting an estimated $1.1M.
- 52 institutional investors held AN2 Therapeutics (ANTX) as of Q1 2026, up from 38 in Q4 2025.
- Funds reported $74.8M of AN2 Therapeutics stock for Q1 2026, up 657% quarter-over-quarter.
- 25 funds opened new AN2 Therapeutics positions in Q1 2026 and 10 closed out, a net change of +15 holders.
- The largest AN2 Therapeutics buyer in Q1 2026 was Vivo Capital, an estimated $6.51M added.
- The largest AN2 Therapeutics seller in Q1 2026 was Peapod Lane Capital, an estimated $1.1M sold.
Based on aggregated 13F filings for Q1 2026.